Hester Biosciences Ltd
Hester Biosciences Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Company aims to steadily grow the bottom line despite Q3 dip, with targets better than last 2-3 years. Management acknowledges Q3 earnings were disappointing but is confident of recovery and improved performance in upcoming quarters.
From Hester Biosciences Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Company aims to steadily grow the bottom line despite Q3 dip, with targets better than last 2-3 years.
- Focus on expanding vaccine portfolio with new vaccines, including Avian Influenza vaccine launch expected next financial year.
- Significant growth expected from Petcare division, which showed 105% Q3 growth; emphasis on new product launches and market penetration.
- Plans to substantially increase health products turnover, potentially exceeding vaccine sales in the coming years.
- African market, especially Tanzania and Ethiopia, is anticipated to contribute a big leap in revenue in next two quarters and beyond.
- Government vaccination programs (e.g., PPR, Goat Pox) tender activity expected to continue steadily supporting sales.
2 more points from Hester Biosciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capacity utilization in India is around 70%, with other countries (Nepal, Africa) much lower (10-20%), indicating enough existing capacity for growth in the next 2 years.
- No immediate plans for capacity expansion in India as current capacity is sufficient for near-term growth.
- Company has internal budgets and forecasts ready but refrains from giving explicit guidance on CAPEX or growth.
- Focus remains on improving profitability and operational efficiency rather than immediate capital expansion.
2 more points from Hester Biosciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders in numerical terms.
- However, it indicates ongoing government tenders, especially for PPR and goat pox vaccines under the National Animal Disease Control Program.
- Tanzania tenders have been published and awarded; supplies are set to begin.
- The company is actively participating in international tenders and trade sales across Africa, with expectations of increased business in the coming quarters.
- There are inquiries for exporting Avian Influenza vaccines to the Middle East and Africa.
2 more points from Hester Biosciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hester Biosciences Ltd Q3 FY25 results?
Company aims to steadily grow the bottom line despite Q3 dip, with targets better than last 2-3 years. Management acknowledges Q3 earnings were disappointing but is confident of recovery and improved performance in upcoming quarters.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
Current capacity utilization in India is around 70%, with other countries (Nepal, Africa) much lower (10-20%), indicating enough existing capacity for growth in the next 2 years.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.